GlassScriptPhysician profile
Zeeshan Sheriff
NPI 1326691700
$982.57
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.10 · 2020: $173 · 2021: $368 · 2022: $356 · 2023: $37.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $37.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $37.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $169.33 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $165.69 | 2021-2023 | Camzyos |
| Gilead Sciences, INC. | $163.94 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.21 | 2020-2022 | |
| Pfizer INC. | $84.89 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $81.40 | 2019-2021 | |
| Abbvie INC. | $57.75 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.00 | 2022 | |
| Allergan, INC. | $24.95 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $22.60 | 2023 | Eylea Hd |
| Jazz Pharmaceuticals INC. | $18.92 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.45 | 2022 | |
| Karyopharm Therapeutics INC. | $14.85 | 2022 | |
| Glaxosmithkline, LLC. | $11.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zeeshan Sheriff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.